Stein Gold L, Eyerich K, Sofen H, Herranz P, Kircik L, Bewley T, Wolf E, Gallo G, Ding Y, Yang FE, Pau-Charles I, Gooderham M. Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. J of Skin [Internet]. 2023Nov.13 [cited 2024Sep.20];7(6):s274. Available from: https://dermsquared.com/skin/article/view/2385